MAPT and Alzheimer disease: Nonetheless, CSF Aβ42 and Tau measurements are currently considered a valid and accurate biomarker for the diagnosis of AD, along with amyloid Positron Emission Tomography (PET) tracers [1,16,17], but they display insufficient specificity between various neurological disorders and dementia [11,18,19,20].